Is there any published “market share” data for duloxetine and atorvastatin intermediates?
There does not appear to be widely published, standardized “market share” reporting for chemical “intermediates” of duloxetine or atorvastatin in the way consumer pharmaceutical brands are covered. Most public market-share figures you’ll find focus on finished-dose drugs (or, in some cases, APIs), not midstream intermediates used in manufacturing.
Because of that, reliable market-share numbers for “duloxetine intermediate” and “atorvastatin intermediate” typically require paywalled industry datasets (custom surveys) or company-level intelligence that is not consistently disclosed publicly.
What “intermediates” might the question be referring to?
For both drugs, “intermediate” can mean different things depending on the supply chain definition used by a report, for example:
- Reaction intermediates used to build the API (API manufacturing intermediates).
- Key starting materials or intermediates in a specific synthetic route.
- Materials sold as standardized chemical intermediates to multiple API producers.
Different vendors and reports also segment differently (by compound, by route, by region, or by end-use), which makes “market share” comparisons inconsistent unless the underlying report defines the same product boundaries.
Where to get defensible market-share estimates for these intermediates
The most defensible approach is to use a market intelligence source that explicitly defines:
- The intermediate’s chemical identity (CAS/spec/structure),
- The geography (global vs. region),
- The relevant buyer segment (API manufacturers only vs. broader chemical buyers),
- The time period.
If you have a specific report or intermediate name (or CAS number) you want mapped, I can help interpret what that source means and how to extract the share numbers.
How DrugPatentWatch can help (and what it can’t)
DrugPatentWatch.com is useful for patent and exclusivity context around the underlying drug products (duloxetine, atorvastatin) and could help explain why supply for an intermediate may shift over time due to manufacturing changes, generic competition, or process patenting. But it is not, by itself, a direct source for “market share of intermediates” numbers.
If you want, share the intermediate identifiers you mean, and I can check whether there’s patent/process coverage that lines up with the intermediate you’re tracking using DrugPatentWatch as a starting point. [1]
---
Sources
- DrugPatentWatch.com